Showing 20 of 162 recruiting trials for “nasopharyngeal-carcinoma”
Perioperative Analgesia Modes in Minimally Invasive Esophagectomy
🏥 Cancer Institute and Hospital, Chinese Academy of Medical Sciences📍 1 site📅 Started Oct 2022View details ↗
RecruitingNCT06515964 ↗
China Early Esophageal Cancer Cohort
RecruitingNCT06009705 ↗
Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer
👨⚕️ Wenbin Shen, PhD, Hebei Medical University Fourth Hospital📍 1 site📅 Started Oct 2022View details ↗
RecruitingNCT05858385 ↗
Predictive Study on Acute Radiation Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients
🏥 Affiliated Cancer Hospital & Institute of Guangzhou Medical University📍 1 site📅 Started Sep 2022View details ↗
SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer
Optimization of Cervical Nodal CTV for Early and Medium Stage NPC
Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG)
Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
RecruitingNCT05707819 ↗
Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
👨⚕️ Xiao-Dong Zhu, Doctor, Cancer Hospital of Guangxi Medical University📍 1 site📅 Started Jul 2022View details ↗
RecruitingNCT05443841 ↗
Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
RecruitingNCT06393140 ↗
The Study on the Mechanism of Radiotherapy-elicited Immune Response
Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma
Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA)
🏥 Federal Research Institute of Pediatric Hematology, Oncology and Immunology📍 1 site📅 Started May 2022View details ↗
Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
Surgery or Chemoradiotherapy for Cervical Esophageal Cancer
👨⚕️ Jie He, MD, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College📍 1 site📅 Started Apr 2022View details ↗
Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →